719 related articles for article (PubMed ID: 22734512)
1. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
2. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Wyndaele JJ
BJU Int; 2012 Jul; 110(2 Pt 2):E143. PubMed ID: 22734513
[No Abstract] [Full Text] [Related]
3. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
[TBL] [Abstract][Full Text] [Related]
4. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Kaku S
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):71-8. PubMed ID: 23224420
[TBL] [Abstract][Full Text] [Related]
5. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
Streng T; Andersson KE; Hedlund P; Gratzke C; Baroni E; D'Ambrosio D; Benigni F
BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
[TBL] [Abstract][Full Text] [Related]
6. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.
Maruyama I; Yonekubo S; Tatemichi S; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
J Smooth Muscle Res; 2012; 48(5-6):115-24. PubMed ID: 23538508
[TBL] [Abstract][Full Text] [Related]
7. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
8. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
[TBL] [Abstract][Full Text] [Related]
9. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
[TBL] [Abstract][Full Text] [Related]
10. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies.
Sugaya K; Yamagami H; Nishijima S; Kadekawa K; Hizue M; Ito Y; Yamada S
Low Urin Tract Symptoms; 2020 May; 12(2):173-179. PubMed ID: 31758673
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
14. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.
Hedlund P; Streng T; Lee T; Andersson KE
J Urol; 2007 Jul; 178(1):326-31. PubMed ID: 17507042
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
16. Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Fey TA; Gopalakrishnan M; Strake JG; King LL; Brioni JD; Sullivan JP; Coghlan MJ; Brune ME
Neurourol Urodyn; 2003; 22(2):147-55. PubMed ID: 12579633
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
19. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
20. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.
Aizawa N; Homma Y; Igawa Y
Eur Urol; 2012 Dec; 62(6):1165-73. PubMed ID: 22981677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
